Bio-Techne recently agreed to be acquired by Merck KGaA. The proposed transaction is expected to strengthen Merck’s position in high-growth life science markets. The deal was cited alongside Merck’s increased 2026 outlook and stronger second-quarter results, but the reported coverage did not disclose a transaction value or closing timeframe.
Key facts
California State Teachers Retirement System lifted its position in Bio-Techne Corp (NASDAQ: TECH) by 24.1% in the first quarter. source
The institutional investor owned 184,164 shares of the biotechnology company's stock after purchasing an additional 35,772 shares during the quarter. source